Working… Menu

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01098344
Recruitment Status : Completed
First Posted : April 2, 2010
Last Update Posted : October 14, 2015
Information provided by (Responsible Party):
Cancer Research UK

Brief Summary:

RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving MK0752 together with gemcitabine hydrochloride may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of giving MK0752 together with gemcitabine hydrochloride and to see how well it works in treating patients with stage III or IV pancreatic cancer that cannot be removed by surgery.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: Notch signaling pathway inhibitor MK0752 Drug: gemcitabine hydrochloride Other: imaging biomarker analysis Other: laboratory biomarker analysis Other: pharmacological study Phase 1

Detailed Description:



  • To determine the recommended phase II dose of MK0752 in combination with gemcitabine hydrochloride in patients with unresectable stage III and IV pancreatic cancer. (Phase I)


  • To evaluate tumor response in patients treated with this regimen.
  • To determine the time to disease progression and 6 months and 1-year survival.
  • To determine the percentage of change in CA19-9 levels.


  • To assess target inhibition of MK0752 in plasma.
  • To explore the feasibility of measuring MK0752 levels in tumor tissue.
  • To establish relationships between measures of tumor expression of molecular target and objective tumor response.
  • To determine the pharmacokinetic profile of MK0752 in plasma when administered with and without gemcitabine hydrochloride.

OUTLINE: This is a multicenter, phase I, dose-escalation study of MK0752 and gemcitabine hydrochloride.

Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients receive oral MK0752 on days -14, -7, 1, 8, 15, and 22 in course 1 only and on days 1, 8, 15, and 22 beginning in course 2 and for all subsequent courses. Treatment with MK0752 and gemcitabine hydrochloride repeats every 28 days* for 6 courses in the absence of disease progression or unacceptable toxicity.

NOTE: *The first course is 42 days.

Patients undergo biopsy of tumor at baseline and on day -7. Tumor samples are analyzed to determine Notch pathway inhibition via IHC and qualitative RT-PCR analysis and for MK0752 concentrations. Hair follicle (from the head) samples are collected at baseline and on day -7 to determine Notch pathway inhibition via RT-PCR. Blood samples are collected periodically to determine changes in CA 19-9 levels and MK0752 concentrations.

After completion of study treatment, patients are followed for 28 days and then every 2 months for 1 year. Patients will then be followed up as part of their normal clinic visits for up to one year after the last patient was treated on the study.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Cancer Research UK Phase I Trial of an Oral Notch Inhibitor (MK-0752) in Combination With Gemcitabine in Patients With Stage III and IV Pancreatic Cancer
Study Start Date : April 2010
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Maximum-tolerated dose of MK0752 in combination with gemcitabine hydrochloride OR the single agent recommended Phase II dose in combination with either 800 mg/m² or 1000 mg/m² as agreed by DDO and clinicians
  2. Adverse event and severity according to NCI CTCAE Version 4.02

Secondary Outcome Measures :
  1. Complete response, partial response, or stable disease as defined by RECIST criteria
  2. Progression-free survival
  3. Survival at 1 year
  4. Percentage change in CA19-9 levels
  5. Plasma concentrations of MK0752

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed ductal adenocarcinoma of the pancreas

    • Stage III and IV, unresectable disease
  • Assessable disease by endoscopic ultrasound or CT guidance
  • Tissue that is assessed by the Investigator as being accessible to biopsy - for patients recruited to dose escalation phase where three previous patients have not already provided biopsies
  • No known brain metastases

    • Patients with stable symptoms within the past 4 weeks, on a stable dose of steroids, and able to give informed consent are eligible


  • WHO performance status 0-1
  • Life expectancy ≥ 12 weeks
  • Hemoglobin ≥ 9.0 g/dL
  • Absolute neutrophil count ≥ 1.5 x 10^9/L
  • Platelet count ≥ 100 x 10^9/L
  • Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • ALT ≤ 2.5 times ULN (≤ 5 times ULN if due to liver metastases)
  • PT ≤ 1.5 times ULN
  • Creatinine clearance ≥ 50 mL/min (uncorrected)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use two forms of highly effective contraception (females) 4 weeks prior to, during, and for 6 months after completion of study therapy or 1 form of highly effective contraception (males) during and for 6 months after completion of study therapy
  • Written (signed and dated) informed consent and capable of cooperating with treatment and follow-up
  • No nonmalignant systemic disease, including active uncontrolled infection, that confers a high medical risk to the patient
  • No known serologically positive HIV or hepatitis B or C infection
  • No other concurrent malignancies except adequately treated cone-biopsied carcinoma in situ of the uterine cervix, basal or squamous cell carcinoma of the skin, or cancer survivors who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease ≥ 5 years, and are deemed at negligible risk for recurrence
  • No concurrent congestive heart failure
  • No prior history of cardiac disease (New York Heart Association class III-IV disease), cardiac ischemia, or cardiac arrhythmia
  • No other condition that, in the investigator's opinion, would not make the patient a good recommendation for the clinical trial


  • See Disease Characteristics
  • Recovered from prior treatments
  • Previous chemotherapy for advanced disease is permitted. If gemcitabine treatment was given previously, the patient must have tolerated a dose of at least 800mg/m2. Previous chemotherapy for malignant disease must be complete at least 3 weeks before treatment on this trial (six weeks for mitomycin C)
  • No major thoracic or abdominal surgery from which the patient has not yet recovered
  • No concurrent participation or planned participation in another interventional clinical study

    • Concurrent participation in an observational study allowed
  • No concurrent warfarin

    • Low molecular weight heparin allowed
  • No concurrent radiotherapy (except palliative for bone pain), endocrine therapy, or immunotherapy
  • No other concurrent anticancer therapy or investigational drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01098344

Layout table for location information
United Kingdom
Addenbrooke's Hospital
Cambridge, England, United Kingdom, CB2 2QQ
Leicester Royal Infirmary
Leicester, England, United Kingdom, LE1 5WW
Barts and the London School of Medicine
London, England, United Kingdom, EC1M 6BQ
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom, G12 0YN
St James' Hospital
Leeds, United Kingdom, L59 7TF
Sponsors and Collaborators
Cancer Research UK
Layout table for investigator information
Principal Investigator: Duncan Jodrell, MD Cambridge University Hospitals NHS Foundation Trust
Layout table for additonal information
Responsible Party: Cancer Research UK Identifier: NCT01098344    
Other Study ID Numbers: CDR0000669535
First Posted: April 2, 2010    Key Record Dates
Last Update Posted: October 14, 2015
Last Verified: October 2015
Keywords provided by Cancer Research UK:
stage III pancreatic cancer
stage IV pancreatic cancer
duct cell adenocarcinoma of the pancreas
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs